Pricing Log in Create free account
Friday 6 November 2026 Export AUPH’s income statement to Excel — free account

Aurinia Pharmaceuticals Inc

AUPH Healthcare Biotechnology

Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.

Revenue
+13.9%
EPS
0.00%
Free cash flow
+4.41%
Total debt
−30.0%

Quarter to September 2026, against a year earlier

16.28 0.07 +0.43%
Market cap
$2.2B
P/E
6.8×
Fwd P/E
17.6×
Dividend yield
—
F-score
8/9
Altman Z
7.86
Beneish M
−0.88
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Aurinia Pharmaceuticals Inc (AUPH) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Aurinia Pharmaceuticals Inc (AUPH) trades at a EV/Sales of 5.3×. Over the past ten years it has ranged from 1.6× (December 2022) to 13,487× (October 2020); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 6.4× 51.63%
FY2024 4.2× (24.75%)
FY2023 5.6× 62.57%
FY2022 3.4× (93.75%)
FY2021 54.8× 120.35%
FY2020 24.9× (99.50%)
FY2019 4,965× 408.19%
FY2018 977× 104.61%
FY2017 477× 128.11%
FY2016 209× (23.13%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 5.3× (8.24%)
Jun 2026 5.8× 6.16%
Mar 2026 5.5× (13.89%)
Dec 2025 6.4× 45.47%
43 more quarters

Against its own ten years

Low 1.6× High 13,487×
Ten-year median 223×
Current reading's percentile 20

EV/Sales against peers

Company EV/Sales
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −1.3×
VERA Vera Therapeutics, Inc. compare n/m
BHVN Biohaven Ltd. compare 2.2×
AUPH Aurinia Pharmaceuticals Inc 5.3×
ADMA ADMA Biologics Inc compare 5.8×
VCEL Vericel Corporation compare 7.6×
PVLA Palvella Therapeutics, Inc. compare 48.1×
IMNM Immunome, Inc. compare 121×
CLDX Celldex Therapeutics, Inc. compare 1,691×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on AUPH